US2023087359A1PendingUtilityA1

Cannabinoid compositions and methods of use thereof

62
Assignee: DAY THREE LABS MFG INCPriority: Oct 25, 2017Filed: Nov 21, 2022Published: Mar 23, 2023
Est. expiryOct 25, 2037(~11.3 yrs left)· nominal 20-yr term from priority
Inventors:William Z. LevineShimon LechtOlga Gabay
A61K 36/3482A61K 31/658A61P 25/20A61K 9/007A61K 9/0043A61K 9/0053A61K 2300/00A61K 36/185A61K 31/352A61K 31/05
62
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Embodiments relate to a method for treatment of a sleep disorder and to compositions comprising tetrahydrocannabinol (THC), cannabidiol (CBD), and cannabinol (CBN), wherein the ratio of THC:CBD:CBN by weight is A:B:C where A is between 0.0001 and 1, B is 1, and C is between 0.05 and 1. Optionally A is between 0.001 and 0.02, B is 1 and C is between 0.2 and 0.7.

Claims

exact text as granted — not AI-modified
We claim: 
     
         1 . A composition comprising a tetrahydrocannabinol (THC), a cannabidiol (CBD), and a cannabinol (CBN), wherein the ratio of THC:CBD:CBN by weight is A:B:C where A is 0.02, B is 1 and C is between 0.2 and 0.7. 
     
     
         2 . The composition according to  1  wherein C is 0.25. 
     
     
         3 . The composition according to  1  wherein C is 0.2. 
     
     
         4 . The composition according to  claim 1  wherein C is 0.5. 
     
     
         5 . The composition according to  claim 1  comprising less than 5% of other cannabinoids relative to the combined weight of THC, CBD and CBN in the composition. 
     
     
         6 . The composition according to  claim 5  wherein the composition comprises no cannabinoids other than THC, CBD and CBN. 
     
     
         7 . The composition according to  claim 1  wherein the composition is prepared for administration via the parenteral, dermal, pulmonary, nasal, oral, anal or oral cavity route. 
     
     
         8 . The composition according to  claim 7  prepared for administration via the oral route. 
     
     
         9 . The composition according to  claim 1  further comprising a carrier or an inactive ingredient. 
     
     
         10 . The composition according to  claim 1  in the form of a tablet, liquid filled capsule, a soft-gel capsule, or a solution, emulsion, suspension or syrup. 
     
     
         11 . The composition according to  claim 1  wherein the cannabinoid is in the form of whole plant extract.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.